ABSTRACT
Background: Chronic urticaria (CU) is a common skin disorder characterized by the recurrent appearance of wheals typically associated with pruritis and/or angioedema for more than 6 weeks. It has a significant impact on patient’s quality of life (QoL). Hence it is of utmost importance to identify the impact of CU on the patient’s life and psychiatric comorbidities associated with it. The objectives of the study were to assess the effect of chronic urticaria on the quality of life of the patient; to assess the depression in patients with chronic urticaria; to assess the anxiety in patients with urticaria.Methods: A total of 106 patients with chronic urticaria attending allergy clinic, KIMS Hospital during November-January 2019 (3 months) were included in the study. Informed consent was obtained. Each patient was interviewed using pretested questionnaire developed using chronic urticaria on quality of life: (CU-Q2oL), patient health questionnaire-9 (PHQ-9) and general anxiety disorder-7 (GAD-7). Data was entered in Epi-info7 and descriptive statistics were used.Results: There were 43 (40.6%) males and 63 (59.4%) females. The mean age of the patients was 36.5±11.7 years. Quality of life was affected A lot in 9.5% of the patients and is somewhat affected in 38.7% of the CU patients. As much as 42.5% of them suffered from some grade of depression and 34.9% of them suffered from anxiety.Conclusions: Chronic urticaria has a significant role in impairment of QOL and also leads to mental illnesses such as depression and anxiety.
ABSTRACT
Backgroundand Aims: Lymphatic filariasis (LF) is the most debilitating and disfiguring among all diseases. The National HealthPolicy (2002) had set the goal of elimination of LF in India by 2015. The concept of mass drug administration (MDA) is to approachevery individual in the target community and administer an annual single dose of antifilarial drugs (diethylcarbamazine andalbendazole).Objectives: The objectives of this study were (1) to find the coverage and compliance of MDA at Dakshina Kannada district and (2) toassess the knowledge of responsible adult respondent regarding elephantiasis/filariasis and MDA program.Materials and Methods: The present study was conducted to evaluate the coverage and compliance of MDA in Dakshina KannadaDistrict which was held on January 23, 2012. The evaluation was conducted for 1 week by a team of investigators. A total of 232 houseswere visited randomly in four clusters (1 in urban + 3 in rural area) covering of 982 beneficiaries between the age group of 2 and 60 yearsof age in pre-designed and semi-structured pro forma.Results: The coverage of MDA was 84%, and compliance among those who received the tablets was 80.24%. There was marginallybetter coverage in urban areas (89.27%) compared to rural area (82.41%), and compliance was better in rural areas (87.94%) comparedto urban area (63.18%). The coverage compliance gap which shows why people do not consume the tablet was 3.74%, and the effectivecoverage rate was 67.41%. The coverage was maximum, i.e., 91.3% in Kalladka (cluster 3) and minimum, i.e., 76.21% in Koila (cluster 2),whereas compliance was maximum, i.e., 90.73% in Koila (cluster 2) and minimum, i.e., 63.18% in Attavara (cluster 1).Conclusion: The coverage and compliance rate in Dakshina Kannada district were 84.01% and 80.24%, respectively, with effectivecoverage rate of 67.41%. Awareness regarding MDA program was poor